JP4247154B2 - PPARγ活性化剤 - Google Patents
PPARγ活性化剤 Download PDFInfo
- Publication number
- JP4247154B2 JP4247154B2 JP2004153685A JP2004153685A JP4247154B2 JP 4247154 B2 JP4247154 B2 JP 4247154B2 JP 2004153685 A JP2004153685 A JP 2004153685A JP 2004153685 A JP2004153685 A JP 2004153685A JP 4247154 B2 JP4247154 B2 JP 4247154B2
- Authority
- JP
- Japan
- Prior art keywords
- ppar
- present
- extract
- pparγ
- pparα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012190 activator Substances 0.000 title claims description 19
- 108010016731 PPAR gamma Proteins 0.000 title claims description 18
- 102000000536 PPAR gamma Human genes 0.000 title claims 5
- 239000000284 extract Substances 0.000 claims description 31
- 244000294611 Punica granatum Species 0.000 claims description 19
- 235000014360 Punica granatum Nutrition 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 39
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 39
- 230000004913 activation Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 19
- 240000006053 Garcinia mangostana Species 0.000 description 18
- 235000017048 Garcinia mangostana Nutrition 0.000 description 18
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 18
- 102000023984 PPAR alpha Human genes 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 235000014826 Mangifera indica Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 241000545263 Salacia <hydroid> Species 0.000 description 11
- 235000006886 Zingiber officinale Nutrition 0.000 description 11
- 235000008397 ginger Nutrition 0.000 description 11
- 235000004936 Bromus mango Nutrition 0.000 description 10
- 235000009184 Spondias indica Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 235000013402 health food Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241001093152 Mangifera Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 240000007228 Mangifera indica Species 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000007964 xanthones Chemical class 0.000 description 5
- 244000062241 Kaempferia galanga Species 0.000 description 4
- 235000013421 Kaempferia galanga Nutrition 0.000 description 4
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229940043357 mangiferin Drugs 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 241000051611 Salacia oblonga Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000001841 zingiber officinale Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- VHRUMKCAEVRUBK-WKELIDJCSA-N (z)-7-[(1s,5e)-5-[(z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC\C=C/C=C1\[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-WKELIDJCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000832224 Hypericaceae Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000488583 Panonychus ulmi Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 244000087020 Salacia prinoides Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 244000081822 Uncaria gambir Species 0.000 description 1
- 241000963384 Zingiber mioga Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- -1 fruit Natural products 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- CONWAEURSVPLRM-UHFFFAOYSA-N lactofen Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC(C)C(=O)OCC)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 CONWAEURSVPLRM-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
マンゴー果実は、市販のもの(フィリピン産)を購入して核(種子を包含する組織)をステンレス製の包丁で除去し、すぐに凍結乾燥した。乾燥した結果、その重量は乾燥前の1/10〜1/12となった。その他、マンゴスチン(ベトナム産)の果皮,サラシア オブロンガ根,ザクロ花,金時ショウガ(静岡産またはベトナム産),大高良姜(ベトナム産)は、粗乾燥したものを材料として用いた。また、アセンヤクは、粉末にして用いた。
先ず、細胞用基本培地であるDMEM/F-12(イントロゲン社製)に、牛血清(終濃度:10%)、ペニシリン(100単位/mL)、ストレプトマイシン(100μg/mL)、1-グルタミン(1%)およびHEPES(15mM)を添加し、細胞用培地を調製した。この細胞用培地へヒト胚由来腎細胞(HEK-293)を添加し、培養した。
上記試験例1において調製したものと同様の96穴ウェルプレートへ、PPARαの合成拮抗剤(合成アンタゴニスト)であるMK-866(BIOMOL研究所製)の0.1μM水溶液を加え、1時間インキュベートした後に、上記試験例1と同様に各サンプルを添加して処理した。その結果を図2に示す。
細胞用基本培地であるRPMI1640(日水製薬社製)に、牛血清(終濃度:10%)、ペニシリン(100単位/mL)、ストレプトマイシン(100μg/mL)および1-グルタミン(1%)を添加し、細胞用培地を調製した。別途、ATCC(American Type Culture Collection)から購入したTHP−1ヒト単球細胞を95% O2,5% CO2,37℃で加湿し、GIBCO社製の培養器を用いて培養した。以下の実験では、5〜20μm通過分の単球を用いた。また、上記製造例1で得たサラシア根,マンゴー果実,マンゴスチン果皮,ザクロ花,金時ショウガ,大高良姜の各抽出物およびアセンヤクの50または100μg/mLDMSO溶液と、比較のためにPPARγの合成活性化剤であるGW1929(シグマ−アルドリッチ社製)の3μg/mL水溶液を調製した。また、試験例1と同様に、マンギフェリン等の溶液も調製した。
Claims (4)
- ザクロ(Punica granatum)の花の水系溶媒抽出物を有効成分として含有することを特徴とするPPARγ活性化剤。
- 水系溶媒が、水、低級アルコール、または水と低級アルコールとの混合溶媒である請求項1に記載のPPARγ活性化剤。
- 低級アルコールが、メタノール、エタノール、イソプロパノール、またはt−ブチルアルコールである請求項1または2に記載のPPARγ活性化剤。
- さらにアセンヤクを含有する請求項1〜3のいずれかに記載のPPARγ活性化剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004153685A JP4247154B2 (ja) | 2004-03-18 | 2004-05-24 | PPARγ活性化剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004077940 | 2004-03-18 | ||
JP2004153685A JP4247154B2 (ja) | 2004-03-18 | 2004-05-24 | PPARγ活性化剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008263855A Division JP4266386B2 (ja) | 2004-03-18 | 2008-10-10 | PPARα活性化剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005295991A JP2005295991A (ja) | 2005-10-27 |
JP4247154B2 true JP4247154B2 (ja) | 2009-04-02 |
Family
ID=35328283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004153685A Expired - Lifetime JP4247154B2 (ja) | 2004-03-18 | 2004-05-24 | PPARγ活性化剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4247154B2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618662B2 (en) * | 2004-12-22 | 2009-11-17 | Avon Products, Inc | Use of natural plant extracts in cosmetic compositions |
JP5638180B2 (ja) | 2007-09-06 | 2014-12-10 | 富士フイルム株式会社 | サラシア属植物の抽出物とフラボノイドを含有する食品 |
JP2010077039A (ja) * | 2008-09-24 | 2010-04-08 | Fujifilm Corp | 免疫賦活剤または抗アレルギー剤 |
WO2010100653A2 (en) * | 2009-02-02 | 2010-09-10 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
JP2010195831A (ja) * | 2010-06-12 | 2010-09-09 | Lotte Co Ltd | IκBキナーゼ阻害剤 |
CN102618071A (zh) * | 2012-03-08 | 2012-08-01 | 桂林理工大学 | 一种超声波法提取山竹子果皮色素的方法 |
JP6096158B2 (ja) * | 2014-09-17 | 2017-03-15 | 富士フイルム株式会社 | 免疫賦活剤または抗アレルギー剤 |
JP2022175444A (ja) * | 2021-05-13 | 2022-11-25 | 小林製薬株式会社 | 夜間頻尿、中途覚醒又は頻尿の予防又は改善剤 |
-
2004
- 2004-05-24 JP JP2004153685A patent/JP4247154B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2005295991A (ja) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pastore et al. | Potential health benefits of green tea (Camellia sinensis): a narrative review | |
Kamagaté et al. | Ethnobotany, phytochemistry, pharmacology and toxicology profiles of Cassia siamea Lam | |
Choi et al. | Protective effects of black rice bran against chemically-induced inflammation of mouse skin | |
JP5563824B2 (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)のリガンド剤 | |
CN102292093B (zh) | 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 | |
KR101523820B1 (ko) | 섬쑥부쟁이 추출물을 유효성분으로 함유하는 비만 또는 대사성질환의 예방 또는 치료용 약학적 조성물 | |
Hwang et al. | Oxyresveratrol-containing Ramulus mori ethanol extract attenuates acute colitis by suppressing inflammation and increasing mucin secretion | |
KR20160139072A (ko) | 딱지꽃 추출물 또는 이로부터 유래된 폴리페놀계 화합물을 유효성분으로 하는 대사성 질환 예방 및 치료용 약학적 조성물 | |
JP2012149004A (ja) | 核内受容体の賦活剤 | |
JP4247154B2 (ja) | PPARγ活性化剤 | |
KR101965061B1 (ko) | 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
Reza et al. | Pharmacological investigation of analgesic and antipyretic activities of methanol extract of the whole part of Aeginetia indica | |
KR20180107439A (ko) | 금방동사니 추출물을 포함하는 항비만 조성물 | |
JP2004161656A (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
JP4266386B2 (ja) | PPARα活性化剤 | |
KR102438938B1 (ko) | 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물 | |
KR102241169B1 (ko) | 두메부추 추출물을 포함하는 간 섬유화 또는 간경화 예방, 개선 또는 치료용 조성물 | |
Maharana et al. | Assessment of antihyperglycaemic and antioxidant and potential of leaves of Solanum nigrum Linn. in alloxan induced diabetic rats | |
KR20150012926A (ko) | 구절초 추출물을 포함하는 항비만 조성물 | |
WO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
WO2020153413A1 (ja) | PPARγ活性化用組成物及び糖取込み促進能向上用組成物 | |
KR101901491B1 (ko) | 밤꽃으로부터 추출된 앱솔루트 또는 신나밀 알코올을 포함하는 항비만 조성물 | |
JPWO2005082391A1 (ja) | ヒトβ3アドレナリン受容体アゴニスト剤 | |
Alzahrani et al. | Determination of Analgesic Potential of Ethanolic Extract of Brassica campestris Leaves in Rats | |
Badria et al. | Revealing the molecular mechanism of Olea europaea L. in treatment of cataract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070307 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090106 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090109 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4247154 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120116 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120116 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130116 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130116 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140116 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |